|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0024299,
umls-concept:C0027651,
umls-concept:C0078058,
umls-concept:C0086982,
umls-concept:C0205208,
umls-concept:C0242275,
umls-concept:C0796392,
umls-concept:C0920321,
umls-concept:C1256770,
umls-concept:C1628324
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-4-5
|
|
pubmed:abstractText |
Inhibition of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) pathways may result in synergistic antitumour activity. We designed a phase I study to evaluate the combination of vandetanib, an investigational agent with activity against EGF receptor and VEGF receptor 2, and bevacizumab, a monoclonal antibody against VEGF.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Contrast Media,
http://linkedlifedata.com/resource/pubmed/chemical/Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/N-(4-bromo-2-fluorophenyl)-6-methoxy...,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
pubmed-author:AllenDeborahD,
pubmed-author:CaoLiangL,
pubmed-author:ChenAliceA,
pubmed-author:ChenHelenH,
pubmed-author:ChoykePeterP,
pubmed-author:CollinsJerryJ,
pubmed-author:DoroshowJames HJH,
pubmed-author:GutierrezMartin EME,
pubmed-author:HornefferYvonne RYR,
pubmed-author:JuwaraLaminL,
pubmed-author:KimYeong SangYS,
pubmed-author:KummarShivaaniS,
pubmed-author:MelilloGiovanniG,
pubmed-author:MurgoAnthony JAJ,
pubmed-author:TrepelJaneJ,
pubmed-author:TurkbeyIsmail BIB,
pubmed-author:YuYunkaiY
|
|
pubmed:copyrightInfo |
Published by Elsevier Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
997-1005
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21247755-Adult,
pubmed-meshheading:21247755-Aged,
pubmed-meshheading:21247755-Antibodies, Monoclonal,
pubmed-meshheading:21247755-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21247755-Antineoplastic Agents,
pubmed-meshheading:21247755-Contrast Media,
pubmed-meshheading:21247755-Epidermal Growth Factor,
pubmed-meshheading:21247755-Female,
pubmed-meshheading:21247755-Humans,
pubmed-meshheading:21247755-Lymphoma,
pubmed-meshheading:21247755-Magnetic Resonance Imaging,
pubmed-meshheading:21247755-Male,
pubmed-meshheading:21247755-Middle Aged,
pubmed-meshheading:21247755-Neoplasms,
pubmed-meshheading:21247755-Piperidines,
pubmed-meshheading:21247755-Quinazolines,
pubmed-meshheading:21247755-Signal Transduction,
pubmed-meshheading:21247755-Time Factors,
pubmed-meshheading:21247755-Tumor Markers, Biological,
pubmed-meshheading:21247755-Vascular Endothelial Growth Factor A,
pubmed-meshheading:21247755-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
|
|
pubmed:affiliation |
Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA. kummars@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
